Kirkland, Wash.
Went public 8/3/2000 at $14 per share
Filing Range: 7.2 mil. shares @ $10 to $12
Shares Outstanding: 30. mil. shares
Underwriters: Lehman Brothers/Lazard Freres & Co. LLC/ Prudential
Vector Healthcare/Fidelity Capital Markets
Company Counsel: Venture Law Group
Manager Counsel: Mintz Levin Cohn Ferris Glovsky & Popeo
Auditor: PricewaterhouseCoopers LLP
The Company:
Develops biochip technology for the analysis of pharmacological data to predict the effects of promising drugs to fight cancer and immunological diseases.
Venture Backers:
Vulcan Ventures Inc.
Olympic Venture Partners
Tredegar Investments
Pequot Capital Management Inc.
Financing Rounds:
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 04/01/1997 4 Early Stage 17500.1
2 04/01/1999 2 Later Stage 7600.0
3 03/14/2000 4 Later Stage 41581.0
Financials:
(Data in $ millions)
Y/E
12/31/99
Total Revenues: $1.0
Net Income: -19.8